The Food and Drug Administration recently issued a warning to Allergan Inc., stating that the website for Latisse (a prescription eyelash lengthener) is misleading because it omits and minimizes risks associated with the product.
In a letter dated September 10, the FDA warns that latisse.com misbrands Latisse – in violation of the Federal Food, Drug, and Cosmetic Act – because it does not clearly convey the consequences that may result from use of the drug, which include:
Hair growth outside the treatment area
Potential for contamination and infections
Absorption by soft contact lenses
To read the letter in its entirety, click here.